Paeds Vivas · cardiology
Kawasaki disease and coronary complications — branching viva
Branching viva on Kawasaki disease: the clinical criteria and incomplete disease, the ten-day IVIG and aspirin window, IVIG-resistant disease and its escalation, coronary z-score grading and anti-thrombotic management, and the long-term risk of stenosis and myocardial infarction.
On this page & tools
Target exams
Examiner opening (Examiner)
You are the general paediatric registrar in the emergency department. An eighteen-month-old child is brought in febrile and irritable, on day six of fever, with bilateral red eyes without discharge, cracked bleeding lips, a strawberry tongue, a widespread rash, and swollen red palms and soles. Talk me through your assessment and immediate management. [1]
Exemplar opening (Candidate)
This child has a clinical picture strongly suggestive of Kawasaki disease, and because we are on day six of fever the ten-day treatment window is open but narrowing, so I will move quickly. I will confirm the fever duration and the five principal features — bilateral non-purulent conjunctivitis, oral changes, polymorphous rash, extremity changes, and cervical lymphadenopathy — and he already has four of five with the fever, which is complete Kawasaki disease. I will take blood for a full blood count, C-reactive protein, erythrocyte sedimentation rate, albumin and liver function, send a urine for microscopy, and arrange a baseline echocardiogram. While those are running I will start intravenous immunoglobulin at 2 g/kg as a single infusion over ten to twelve hours with high-dose aspirin, because treating within ten days is the single biggest factor preventing coronary aneurysms. [1]
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References6Show ledgerHide ledger
- [1]McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation, 2017.PMID 28356445
- [2]Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med, 1986.PMID 2426590
- [3]Burns JC, Roberts SC, Tremoulet AH, et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health, 2021.PMID 34715057
- [4]Dallaire F, Dahdah N New equations and a critical appraisal of coronary artery Z scores in healthy children. J Am Soc Echocardiogr, 2011.PMID 21074965
- [5]Ghelani SJ, Baker AL, Friedman K, et al. Myocardial Infarction in Kawasaki Disease. J Pediatr, 2025.PMID 40368243
- [6]Tsuda E, Hashimoto S Changes in Coronary Aneurysm Diameters After Acute Kawasaki Disease from Infancy to Adolescence. Pediatr Cardiol, 2021.PMID 34132855